黑龙江省东部地区汉族人群冠心病的危险因素研究

目的 了解黑龙江省东部地区汉族人群冠心病的危险因素,为制定黑龙江省东部地区汉族人群冠心病的的二级预防提供依据。方法 选取2017年1月~12月在佳木斯大学附属第一医院心内科住院的患者,经冠状动脉造影检查或者冠状动脉CTA确诊的冠心病患者228例为冠心病组,同期确诊为非冠心病患者116例为非冠心病组,分别对冠心病组和非冠心病组的资料如性别、年龄、吸烟及饮酒等进行调查,对既往史如高血压病病史等进行调查,把甘油三脂（TG）、胆固醇（TC）、低密度脂胆固醇（LDL-C）、高密度脂胆固醇（HDL-C）及尿酸（UA）等生化指标纳入研究对象里,分析冠心病组与非冠心病组危险因素的差异。结果 冠心病组和非冠心病组在年龄（P＜0.01）、性别（P=0.043,P＜0.05）、高血压病病史（P=0.033,P＜0.05）、糖尿病病史（P=0.015,P＜0.05）、吸烟史 （P=0.048,P＜0.05）、甘油三脂（P=0.006,P＜0.01）、胆固醇（P＜0.05）、低密度脂蛋白胆固醇（P=0.007,P＜0.01）、尿酸（P=0.014,P＜0.05）等研究因素的差异上有统计学意义,两组在高密度脂蛋白胆固醇 （P=0.076,P＞0.05）、饮酒史（P=0.316,P＞0.05）两因素上的差异无统计学意义。结论 针对以上的危险因素,对危险因素采取预防治疗措施,降低黑龙江省东部地区冠心病的发病风险。     

糖、脂类、C反应蛋白与冠心病患者Gensini积分的相关性研究

目的 探讨糖、脂类、C反应蛋白与冠心病患者Gensini积分的相关性.方法 冠心病组选择我院2013年1月至2015年1月收治的冠状动脉硬化性心脏病患者60例,健康组选择我院体检中心同期体检的健康体检者60例,测定总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)、超敏C反应蛋白(CRP)、糖化血红蛋白(HbA1c),并且分析糖脂代谢指标和冠脉病变严重程度、CRP之间的关系.结果 ①与健康组对比,冠心病组HbA1c、TC、TG、LDL-C和HbA1c×LDL-C/HDL-C明显升高,HDL-C明显降低,数据比较差异具有统计学意义,P ＜0.05.②冠心病患者糖脂代谢指标与Gensini积分、CRP的相关性分析显示,HbA1c、LDL-C水平、HbA1c×LDL-C/HDL-C和Gensini积分、CRP呈正相关关系,HDL-C水平和Gensini积分、CRP呈负相关.结论 糖脂代谢与冠状动脉硬化性心脏病患者病情、血清C反应蛋白水平正相关,通过糖脂代谢指标能够对冠状动脉硬化性心脏病患者的病情和血清C反应蛋白进行一定的预测,具有临床检测价值.     

冠心病患者血液粘度与HDL-C和HDL-C/TC的变化及其关系

本文观察了79例CHD患者和125例中老年对照者血液粘度中的ηb低切、ηb高切和ηP以及血脂中的HDL－C和HDL－C／TC。结果表明CHD患者血液粘度呈高粘滞状态，血脂呈低HDL－C状态；对照组仅HDL－C与ηb低切有较好的负相关，而CHD组的HDL－C和HDL－C／TC与ηb低切和ηb高切均有良好的负相关。结果提示在临床上同时检测这些指标并观察其负相关关系，对协助诊断CHD和预测心血管危险因子具有更大价值。     

冠心病患者脂联素水平与脉搏波速度的相关性分析

目的:探讨冠心病患者血清脂联素水平与臂踝脉搏波速度(baPWV)的相关性。方法:收集2008-01至2012-12确诊的50例冠心病住院患者(病例组)和同期体检50例正常人(对照组)。比较两组血清脂联素水平和baPWV的统计学差异,并对冠心病患者血清脂联素水平与baPWV进行相关性分析。结果:病例组血清脂联素水平(7.54±3.08)μg/ml较对照组(9.94±3.51)μg/ml明显降低(P0.01),而baPWV(1654.48±401.77)cm/s较对照组baPWV(1213.39±260.60)cm/s明显加快(P0.01);偏相关分析显示冠心病患者血清脂联素水平与PWV呈显著负相关(r=-0.752,P0.01)。结论:高水平血清脂联素可能是冠心病的保护因素。     

小而密低密度脂蛋白及常见血脂指标与冠心病的相关性研究

目的 探讨血清小而密低密度脂蛋白(small dense low-density lipoprotein, sd-LDL)水平与血清胆固醇(cholesterol,CHO)、甘油三酯(triglyceride, TG)、低密度脂蛋白(low density lipoprotein,LDL)指标与冠心病(coronary heart disease, CHD)的发生发展及各指标之间的相互关系.方法 选取CHD患者87例作为病例组,其中男48例,女39例.纳入109例健康体检者作为对照组,男52例,女57例.采用全自动日立7600仪器,日本积水相关检测试剂测定各组血清CHO、TG、LDL水平,血清sd-LDL水平采用九强小而密低密度脂蛋白测定试剂于雅培C16000仪器上进行测定.采用SPSS 22.0软件进行相关数据分析.结果 病例组血清CHO水平、LDL水平及sd-LDL水平高于正常对照组,差异具有统计学意义(P<0.01).女性病例组TG水平高于对照组,男性及总体病例组与对照组TG水平差异无统计学意义.年龄和sd-LDL水平为冠心病相关的独立危险因素.冠心病患者血清sd-LDL与CHO、TG及LDL水平均呈显著正相关,血清LDL与CHO呈显著正相关(P<0.01).结论 血清sd-LDL是独立的冠心病危险因素,血脂常规项目联合sd-LDL对于冠心病的早期预测可能具有更好的提示和诊断作用.     

Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia

Summary We investigated long-term hypolipidemic effects and clinical safety of simvastatin, a new competitive inhibitor of 3-hydroxy-methylglutaryl coenzyme A reductase in 24 patients with familial and non-familial hypercholesterolemia. Patients received up to 40 mg simvastatin for a period of 30 months. Significant decreases were noted in plasma cholesterol (30%), plasma triglycerides (25%), very low density lipoprotein-cholesterol (26%), and low density lipoprotein-cholesterol (40%), whereas an increase in plasma high density lipoprotein-cholesterol (11%) was observed. Furthermore, the percentage decrease in plasma low density lipoprotein cholesterol was independent of individual baseline concentrations. Simvastatin did not alter the composition of low density lipoproteins or high density lipoproteins. The percentage decrease in total plasma and low density lipoprotein-cholesterol was independent of apoprotein E isoforms and low density lipoprotein-receptor activity as assayed in cultured fibroblasts. The drug therapy was well tolerated and clinical examinations revealed no adverse effects. Clinical chemistry indices and hematological, as well as endocrinological parameters remained within normal limits and ranges.Abbreviations VLDL very low density lipoprotein - LDL low density lipoprotein - HDL high density lipoprotein - CHD coronary heart disease - LDL-C low density lipoprotein-cholesterol - FH familial hypercholesterolemia - HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A - HELP heparin extracorporeal low density lipoprotein precipitation This work was supported by a grant from the Deutsche Forschungsgemeinschaft to A.K. Walli (Wa 458/I-1)Dedicated to Prof. Dr. med. F. Scheler on the occasion of his 65th birthday     

Further studies of Lp(a) lipoprotein/pre-β1,-lipoprotein in patients with coronary heart disease

The present study of 100 patients (46 of whom were included in a previous study) with suspected or proven coronary heart disease (CHD) confirms that Lp(a) lipoprotein and pre-beta1-lipoprotein are closely related, if not identical, and that Lp(a) lipoprotein/pre-beta-lipoprotein occurs more frequently in patients with CHD than in healthy people. Analysis of this lipoprotein component may have predictive value with respect to CHD.     

中国汉族人芳香二烷基磷酸酯酶基因启动子多态性与冠心病的关系

芳香二烷基磷酸酯酶（paraoxonase,PON1)基因启动子区－108（C／T）多态性与人类冠心病（CHD）及其血脂水平的关系。采用多聚酶链反应－限制性长段多态性的分析方法（PCR－RFLP）检测CHD患者PON1基因启动子区－108位点的多态性。结果显示PON1启动子区－108位点存在多态性，出现三种基因型：TT，TC和CC。各等位基因的分布在正常对照组及CHD组之间存在显著性差异，且CC基因型的分布在两组间也有显著差异（P＜0．05）。正常对照组与CHD组间各基因型血浆Apo AI水平无显著性差异；CHD组CC纯合子的血浆高密度脂蛋白胆固醇（HDL－C）水平明显低于对照组（P＜0．05），而两组间TT纯合子和TC杂合子的HDL－C水平无统计学差异。说明该多态性可能与CHD有一定的相关性。     

Anger and impatience/irritability in patients of low socioeconomic status with acute coronary heart disease

This case-control study examines the relationship between anger and impatience/irritability and acute coronary heart disease (CHD) in middle-aged men of low socioeconomic status (SES). Subjects included patients with myocardial infarction (MI) (N=31) or unstable angina (AP) (N=26), who were compared with hospital controls (N=26). In separate multi-variate analyses for each anger scale, MI was associated with Anger-Out and Impatience/Irritability, particularly in the subgroup of patients who did not have a previous MI. The same factors were associated with AP, but only when this acute ischemic event was not preceded by a ML No relationship was found between Trait-Anger and Anger-In and either acute ischemic outcome. The results indicate that particularly overt behavioral expression of anger is related to CHD in lower SES patients and that there is similarity in the behavioral factors associated with acute CHD between low- and high-SES men.     

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

Familial hypercholesterolemia carries a marked increase in the risk of coronary heart disease (CHD), but there is considerable variation between individuals in susceptibility to CHD. To investigate the possible role of lipoprotein(a) as a risk factor for CHD, we studied the association between serum lipoprotein(a) levels, genetic types of apolipoprotein(a) (which influence lipoprotein(a) levels), and CHD in 115 patients with heterozygous familial hypercholesterolemia. The median lipoprotein(a) level in the 54 patients with CHD was 57 mg per deciliter, which is significantly higher than the corresponding value of 18 mg per deciliter in the 61 patients without CHD. According to discriminant-function analysis, the lipoprotein(a) level was the best discriminator between the two groups (as compared with all other lipid and lipoprotein levels, age, sex, and smoking status). Phenotyping for apolipoprotein(a) was performed in 109 patients. The frequencies of the apolipoprotein(a) phenotypes and alleles differed significantly between the patients with and those without CHD. The allele LpS2, which is associated with high lipoprotein(a) levels, was found more frequently among the patients with CHD (0.33 vs. 0.12). In contrast, the LpS4 allele, which is associated with low lipoprotein(a) levels, was more frequent among those without CHD (0.27 vs. 0.15). We conclude that an elevated level of lipoprotein(a) is a strong risk factor for CHD in patients with familial hypercholesterolemia, and the increase in risk is independent of age, sex, smoking status, and serum levels of total cholesterol, triglyceride, or high-density lipoprotein cholesterol. The higher level of lipoprotein(a) observed in the patients with CHD is the result of genetic influence.     

Hypercholesterolemia and LDL apheresis

Several trials have assessed the link between low-density lipoprotein cholesterol (LDL) and the development of coronary heart disease (CHD). LDL apheresis provides an effective role in treating patients with familial hypercholesterolemia (FH) and in preventing the progression of coronary artery disease (CAD). Five different techniques of LDL apheresis are in current use: immunoadsorption (IMA), dextran sulphate-cellulose adsorption (DSA), heparin extracorporeal LDL precipitation system (HELP), double filtration plasmapheresis (DFPP) or lipidfiltration and direct adsorption of lipoprotein using hemoperfusion (DALI). All methods are efficient,but their cost restricts LDL apheresis to the treatment of FH. Indications could include other diseases, but controlled trials are still lacking.     

血脂异常与老年冠心病患者冠脉病变程度的相关性研究

目的 探讨血脂异常与老年冠心病患者冠脉病变程度的相关性。方法 选取2015年5月~2017年1月本院心内科住院的明确诊断为冠状动脉粥样硬化性心脏病（CHD）的150例老年患者设为CHD组。选取同期收治的150例非CHD患者为对照组。比较两组血清中总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平,并计算N-HDL-C、LDL-C/N-HDL-C、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值。比较不同冠脉病变支数、不同病情严重程度的CHD患者的血脂及其比值。对血脂与冠脉病变支数、病情严重程度积分进行相关性分析。结果 CHD组患者LDL-C、TG、TC、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值均高于对照组,HDL-C水平低于对照组,差异均有统计学意义（P＜0.05）;不同冠脉病变支数各亚组间的TC、TG、N-HDL-C水平、TC/HDL-C比值差异存在统计学意义（P＜0.05）;TC、TG、N-HDL-C水平、TC/HDL-C比值均与冠脉病变支数均呈正相关（P＜0.05）;不同病情严重程度亚组间的LDL-C、TC、TG、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C比值差异存在统计学意义（P＜0.05）;CHD患者LDL-C、TC、TG、N-HDL-C水平、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C比值与冠状动脉病变积分均呈正相关（P＜0.05）。结论 可以通过对血脂指标的监测,并计算N-HDL-C、TC/HDL-C、LDL-C/HDL-C、TC/HDL-C、TG/HDL-C值,来评估CHD病情的临床进展。     

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

Genetic variation at the lipoprotein lipase (LPL) locus has been shown to influence plasma lipids and to modulate risk of coronary heart disease (CHD). Recently, we found that the most frequent variant at this locus, involving a C-terminal truncation of two amino acids (Ser447X), was associated with both higher LPL activity and high density lipoprotein cholesterol (HDL-C) in patients with CHD. However, the impact of this S447X variant on lipids and CHD in the general population was hitherto unknown. We, therefore, analyzed a total of 1114 men and 1144 women randomly ascertained from the Framingham Offspring Study (FOS) for the presence of this LPL variant. Carrier frequency of the S447X allele was 17%, and in men carrier status was associated with higher total cholesterol (delta = 6.2 mg/dl, p = 0.03). higher HDL-C (delta = 2.3 mg/dl, p = 0.01), and lower triglyceride (TG) levels (delta = -19.4 mg/dl, p = 0.02). Moreover, in men, the S447X allele conferred significant protection against CHD (odds ratio: 0.43; p = 0.04). These effects on lipids and CHD were not seen in women. Our study represents the first report on the impact of this mutation on CHD in men from the general population, and we conclude, therefore, that the S447X variant may confer significant protection against high TG levels, low HDL-C, and premature CHD in these subjects.     

载脂蛋白E基因多态性与早发冠心病的关系及其对血脂的影响

目的 研究载脂蛋白E（apolipoprotein E,apoE)基因多态性与早发冠心病（coronary heart disease,CHD)的相关关系及其对血脂水平的影响。方法 应用聚合酶链反应－限制性片段长度多态性（polymerase chain reaction-restricted fragment hength polymorphism,PCR-RFLP)基因分析方法,测定52例早发CHD、161例迟发CHD患者和180名对照者的apoE基因型;血脂水平按常规方法测定。结果 发现的5种apoE基因型,分别为E3／3、E4／4、E3／2、E4／3及E4／2。早发CHD组和迟发CHD组apoE4/3基因型和ε4等位基因频率均高于对照组（P＜0．01）;进一步对两组CHD患者的apoE多态性进行分析,发现早发组ε4等位基因频率较迟发组为高（P＜0．05）。apoE各等位基因型之间,TC和LDL－C水平之间存在统计学差异（P＜0．05）。结论 apoE基因多态性与早发CHD的发生发展有关并影响血脂的水平。     

Screening for familial hypercholesterolaemia

Familial hypercholesterolaemia (FH) is an autosomal dominant disorder characterised by increased plasma concentrations of low density lipoprotein (LDL) cholesterol leading to atherosclerosis and premature coronary heart disease (CHD) and death. The clinical diagnosis of FH is based on a personal and family history, physical examination findings and LDL-cholesterol concentrations. FH is primarily caused by mutations in the LDL-receptor gene (LDLR), and less frequently by mutations in genes for APOB and the more recently identified PCSK9. Lifestyle modification and pharmacotherapy can delay or prevent the onset of CHD in FH. It is estimated that only 20% of cases have been diagnosed in Australia and that the majority are inadequately treated. Screening options for FH include population screening (of children or adults), targeted screening of patients with premature CHD and their relatives, or opportunistic screening such as flagging laboratory lipid reports. Cascade screening, a form of targeted screening, is an ethically acceptable, cost-effective strategy for the identification of FH. However, for screening to be successful, medical practitioners need to be aware of the signs and diagnosis of FH and the benefits of early treatment.     

Lipoprotein lipase activity in patients with combined hyperlipidaemia

The aetiology of familial combined hyperlipidaemia remains obscure, with both genetic and environmental factors contributing to the phenotype, which is frequently associated with premature coronary heart disease. We have studied lipoprotein lipase (LPL) activity and hepatic lipase (HL) activity in patients with coronary heart disease to determine whether variation in lipase activities contributes to this phenotype. Forty-one patients (mean age 50 years; 30 male) were selected on the basis of cholesterol levels above 6.5 mmol/l and triglyceride levels above 2.2 mmol/1, with apoprotein B values over the 90th percentile. There was a family history of premature coronary heart disease in 78% and a personal history in 64%, at mean age 44, the patient group therefore predominantly corresponded to the common definition of familial combined hyperlipidaemia, appropriate in the absence of molecular markers. None of the patients was diabetic; hypertension and smoking were not over represented. Blood samples were taken following intravenous administration of heparin (100IU/kg body wt), and LPL and HL activities were measured. Mean post-heparin LPL was significantly lower in patients than controls 10 min after heparin administration (2.98 ± 1.04 and 3.86 ± 0.93 mol ml^-1 h^-1, respectively, P = 0.001), and 37% patients had values below the 10th percentile of controls. Both male and female patients had significantly higher HL activities than their respective controls at 5, 10, 20 and 30 minutes postheparin. As expected, both female patients and controls had lower HL activities than males, although this sex difference did not reach statistical significance in the patient group. Mean lipid and lipoprotein results were: cholesterol 8.2 mmol/1; triglycerides 4.2 mmol/l; high-density lipoprotein cholesterol 0.90 mmol/1; apoprotein Al 122 mg/dl; apoprotein B 171 mg/dl; lipoprotein (a) 23 mg/dl (median 10 mg/dl). High-density lipoprotein cholesterol and triglycerides were negatively correlated (r = -0.26, P = 0.05). HL was significantly related to body mass index at all time points whereas the negative correlation between post-heparin LPL and body mass index was significant only 30 min after heparin administration. Post-heparin LPL was only weakly correlated with triglycerides 10 and 20 min after heparin administration. These lipid and lipoprotein results are clearly potentially atherogenic as indicated by the extent of premature coronary heart disease in the group described. A decrease in LPL activity may contribute to this pattern.Abbreviations FCHL familial combined hyperlipidaemia - CHD coronary heart disease - LPL lipoprotein lipase - HL hepatic lipase - HDL high-density lipoprotein - VLDL very low density lipoprotein; - apo apoprotein - TG triglyceride - BMI body mass index Correspondence to: M. Seed     

血清性激素和尿酸水平与老年男性冠心病的关系

目的:探讨老年男性冠心病与血清性激素和尿酸水平的关系。方法:收集老年男性冠心病(CHD)患者血液标本80例(CHD组)和体检健康老年男性血液标本40例(对照组),平行测定两组标本的血清雌二醇(E2)、孕酮(P)、睾酮(T)、尿酸(UA)以及空腹血糖(FBG)、血脂(BL)水平。结果:CHD组T水平和高密度脂蛋白胆固醇(HDL-C)浓度显著低于对照组(P<0.05或P<0.01),而E2/T、UA、FBG水平显著高于对照组(P均<0.01)。性激素与UA之间未见显著相关性,Logistic回归分析显示,E2/T、UA以及HDL-C与老年男性CHD独立相关。结论:E2/T比值增高、高UA血症以及低HDL-C血症可能是老年男性CHD的独立危险因素。     

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

Hypercholesterolemia is one of the major causes of coronary heart disease (CHD). The genes encoding the low‐density lipoprotein receptor and its ligand apolipoprotein B, have been the two genes classically implicated in autosomal dominant hypercholesterolemia (ADH). Our discovery in 2003 of the first mutations of the proprotein convertase subtilisin kexin 9 gene (PCSK9) causing ADH shed light on an unknown actor in cholesterol metabolism that since then has been extensively investigated. Several PCSK9 variants have been identified, some of them are gain‐of‐function mutations causing hypercholesterolemia by a reduction of low‐density lipoprotein (LDL) receptor levels; while others are loss‐of‐function variants associated with a reduction of LDL‐cholesterol (LDL‐C) levels and a decreased risk of CHD. In this review, we focus on reported variants, and their biological, clinical, and functional relevance. We also highlight the spectrum of hypercholesterolemia or hypobetalipoproteinemia phenotypes that are already associated with mutations in PCSK9. Finally, we present future prospects concerning this therapeutic target that might constitute a new approach to reduce cholesterol levels and CHD, and enhance the effectiveness of other lipid‐lowering drugs. Hum Mutat 0, 1–11, 2008. © 2008 Wiley‐Liss, Inc.     

氧化型高密度脂蛋白与冠状动脉粥样硬化性心脏病的 相关性分析

目的 研究冠状动脉粥样硬化性心脏病（CHD）患者血浆中氧化型高密度脂蛋白（ox-HDL）水平与冠状动脉病变程度（Gensini评分）之间的相关性,ox-HDL与高密度脂蛋白胆固醇（HDL-C）的比值（ox-HDL/HDL-C）相较HDL-C对血浆HDL真实水平的代表性。方法 选取2018年7月~2019年2月于新乡医学院第一附属医院心内科二病区住院行冠状动脉造影被确诊为冠心病的患者84例为实验组,另选取冠状动脉造影正常者44例为对照组,通过酶联免疫吸附剂（ELISA）检测所有研究对象血浆中ox-HDL水平,应用Pearson相关性分析实验组内ox-HDL、ox-HDL/HDL-C分别与Hcy、冠状动脉粥样硬化病变程度（采用Gensini评分评价）的相关性。结果 实验组ox-HDL水平高于对照组,差异具有统计学意义（P＜0.05）;ox-HDL与Gensini评分呈现明显的正相关（r=0.335,P＜0.01）;oxHDL/HDL-C与Gensini评分之间呈显著正相关（r=0.819,P＜0.01）;多因素Logistic回归分析结果表明ox-HDL水平与冠心病的病变程度相关。结论 ox-HDL是冠心病的危险因素,应用ox-HDL及ox-HDL/HDL-C可以更好的评价冠状动脉病变程度以及冠心病患者血浆HDL-C的真实水平,ox-HDL可能会成为动脉粥样硬化的新的危险因素和治疗的新靶点。     

MTHFR基因C667T和A1298C多态位点和高同型半胱氨酸与冠心病的相关性研究

目的探讨亚甲基四氢叶酸还原酶(methylene tetrahydrofolate reductase,MTHFR)基因上C667T和A1298C多态位点与冠心病(coronary heart disease,CHD)的相关性,以及寻找冠心病的发病危险因素。方法随机选取行冠状动脉造影确诊的冠心病患者200例和同期同地区正常对照200例,运用Taqman方法对C667T和A1298C两个多态位点进行基因分型,罗氏生化和发光(Cobas8000)流水线来测定生化指标及血浆高同型半胱氨酸(homocysteine,HCY)、磷酯酶A2(phospholipase A2,PLA2)、血清叶酸水平等。结果冠心病组的体质量指数(body mass index,BMI)、收缩压(systolic pressure,SBP)、脂蛋白a(lipoprotein a,Lp a)、糖化血红蛋白(glycated hemoglobin,HbA1c)、磷脂酶A2、HCY水平均显著高于对照组;而总胆固醇(total cholesterol,TC)、低密度脂蛋白(LDL-C)、血清叶酸则显著低于对照组。对其进行单因素Logistic回归分析发现,除去上述变量,C667T多态位点也是冠心病发病的危险因素;进一步对C667T和A1298C两个多态位点进行分析时发现,C667T多态位点与冠心病存在相关性,冠心病组的T等位频率为39.0%,远高于对照组的22.0%(P=0.045);在显性模型中,CT/TT vs.CC的P值为0.029,OR=2.60,95%CI分别为1.03~6.14;不同基因型趋势检验P=0.016。而A1298C多态位点并未观察到其与冠心病存在相关性。在C667T和A1298C两个多态位点的联合单倍型分析中,发现只有当两个多态位点同时发生突变(T-G型)时,才存在统计学差异(P=0.034,OR=3.54,95%CI=1.10~11.41),单倍型的分布模式在病例和对照组之间有显著差异(P=0.037)。结论MTHFR基因上C667T多态位点与冠心病存在相关性,而A1298C多态位点并未观察到相关性,单倍型分析发现两者同时发生突变时可增加冠心病的发病风险。